We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02945774
Recruitment Status : Recruiting
First Posted : October 26, 2016
Last Update Posted : September 3, 2020
Information provided by (Responsible Party):
Lawson Health Research Institute

Brief Summary:
Neuroinflammation is increasingly implicated as a potential critical pathogenic mechanism in a variety of neurologic and psychiatric disorders. This study will use hybrid PET/MRI imaging to evaluate neuroinflammation and its relationship to cerebral perfusion in frontotemporal dementia (FTD). Patients with FTD will be recruited from the Cognitive Neurology and Aging Brain clinics at Parkwood Institute and will undergo neurocognitive assessment and MRI/PET using the PET ligand FEPPA which binds to activated microglia, a marker of neuroinflammation. Correlations will be conducted to determine whether abnormal neuroinflammation is present in Frontotemporal dementia and whether differential patterns of neuroinflammation are present in different FTD clinical and molecular subtypes, and to determine the relationship between neuroinflammation, cerebral perfusion using arterial spin labeling MRI imaging techniques, and indices of brain structure including volumetric and white matter analysis.

Condition or disease Intervention/treatment Phase
Frontotemporal Dementia Radiation: (18F)-FEPPA Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias
Actual Study Start Date : August 2016
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : August 2023

Arm Intervention/treatment
Experimental: (18F)-FEPPA Radiation: (18F)-FEPPA
PET ligand that binds to activated microglia, a marker of neuroinflammation

Primary Outcome Measures :
  1. Group differences in regional PET FEPPA ligand imaging [ Time Frame: 120 Minutes ]

Secondary Outcome Measures :
  1. Correlation between PET FEPPA ligand images and specified MR images [ Time Frame: 120 Minutes ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Patients diagnosed with a probable Frontotemporal Dementia or neurologically healthy control participants with no history of neurological problems
  2. Study partner is available who has frequent contact with the subject and can accompany the subject to all clinic visits for the duration of the protocol.
  3. Visual and auditory acuity adequate for neuropsychological testing
  4. Good general health with no diseases expected to interfere with the study.
  5. Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal, surgically sterile or practicing an effective form of family planning
  6. Willing to participate in a longitudinal imaging study at 12 months.
  7. Willing to undergo MRI (3Tesla)/ PET scan (with FEPPA ligand) and no medical contraindications to MRI.

Exclusion Criteria:

  1. Any significant neurologic disease other than suspected Frontotemporal Dementia that would better account for symptoms (i.e. frontal lobe stroke).
  2. Screening/baseline MRI scans with evidence of infection, infarction, or other focal lesions. Subjects with multiple lacunes are excluded.
  3. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body that may preclude MRI participation as per MRI screening form.
  4. Major depression, bipolar disorder as described in DSM-IV within the past 1 year. Psychotic features, agitation or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol.
  5. History of schizophrenia (DSM IV criteria).
  6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
  7. Clinically significant abnormalities in B12, or thyroid function tests that might interfere with the study.
  8. Investigational agents are prohibited one month prior to entry and for the duration of the trial.
  9. Exclusion for FEPPA: Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the subject in any given year would exceed the limits of annual and total dose commitment set forth. The current regulation for radiation dose to patient volunteers and health control volunteers are contained within Health Canada's recently amended (June 19, 2012) Regulations Amending the Food and Drug Regulations (Positron-emitting Radiopharmaceuticals). Limitations for effective total body dose is 50 mSv (C.03.305 (c)) which has been increased from the previous values of 20 mSv (Table 1 in INFO-0491).
  10. Exclusion Criteria for controls undergoing arterial line placement: Absent pulse, Thromboangiitis obliterans (Buerger disease), Burns over the cannulation site, Inadequate circulation to the extremity, Raynaud syndrome, Anticoagulation therapy, Atherosclerosis of upper extremity vessels, Coagulopathy, inadequate collateral flow, Infection at the cannulation site, Previous surgery in the area, Synthetic vascular graft.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02945774

Layout table for location contacts
Contact: S Jesso, BA 519-646-6000 cognitiveneurology@sjhc.london.on.ca

Layout table for location information
Canada, Ontario
Parkwood Institute Recruiting
London, Ontario, Canada, N6C 0A7
Contact: S Jesso, BA    519-646-6000      
Sponsors and Collaborators
Lawson Health Research Institute
Layout table for additonal information
Responsible Party: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT02945774    
Other Study ID Numbers: 107561
First Posted: October 26, 2016    Key Record Dates
Last Update Posted: September 3, 2020
Last Verified: September 2020
Keywords provided by Lawson Health Research Institute:
Additional relevant MeSH terms:
Layout table for MeSH terms
Frontotemporal Dementia
Aphasia, Primary Progressive
Pick Disease of the Brain
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Neurodegenerative Diseases
Frontotemporal Lobar Degeneration
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations